Codes ATC: J01DB01
Chronic obstructive pulmonary disease with acute exacerbation Code ICD11: CA22.0
Type de médicament
Chemical agent
Groupes d'antibiotiques
Type de liste
Liste de base
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid ; 250 mg per 5 mL (anhydrous) powder for oral liquid
Oral > Solid: 250 mg (as monohydrate) ; 500 mg (as monohydrate)
Historique des statuts LME
Ajouté pour la première fois en 2017 (TRS 1006)
Modifié en 2021 (TRS 1035)
Adolescents et adultes
Équivalence thérapeutique
La recommandation concerne ce médicament spécifique
Renseignements sur le brevet
Patents have expired in most jurisdictions
Lire la suite sur les brevets.
Recommandation du comité d'experts
The Expert Committee recommended inclusion of a new, higher strength formulation of cefalexin solid oral dosage form on the core list of the EML for the treatment of exacerbations of chronic obstructive pulmonary disease. The Committee noted that the proposed strength formulation is higher than those currently included on the Model List, and is appropriate and aligned to meet recommended doses for treatment of adults, with the advantages of a reduced pill burden.
Résumé des preuves
Most adult patients diagnosed with exacerbations of COPD can be successfully treated with cephalexin 500 mg every 12 hours for 5 days. The higher strength formulation will allow for a reduced pill burden to complete a course of treatment compared to the currently listed 250 mg strength formulation, and should facilitate adherence to treatment.
Recommandations de la LME : Chronic obstructive pulmonary disease with acute exacerbation
Premier choix
Second choix